NCT01287130 2019-12-17AZD6244 With Cetuximab for Solid Tumors and Colorectal CancerNational Institutes of Health Clinical Center (CC)Phase 1 Completed10 enrolled
NCT02586987 2019-11-18A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed58 enrolled
NCT00514761 2014-08-13Phase II Efficacy Study of AZD6244 in Colorectal CancerAstraZenecaPhase 2 Completed64 enrolled